WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555298
CAS#: 2095128-17-7 (free acid)
Description: MA-0204 is a highly potent and selective PPARd modulator (PPARδ EC50 = 0.4 nM; PPARalpha, EC50 == 6,660 nM) that upregulates the expression of FAO genes in human renal proximal tubule cells, resulting in increased mitochondrial fatty acid oxidation. In normal rats undergoing IR-AKI, MA-0204 attenuates the increases of plasma and urinary biomarkers of AKI, improves renal function, mitigates proximal tubular damage and boosts mitochondrial gene expression. MA-0204 is a potential Treatment for Duchenne Muscular Dystrophy (DMD)
MedKoo Cat#: 555298
CAS#: 2095128-17-7 (free acid)
Chemical Formula: C25H27F3N2O4
Exact Mass: 476.1923
Molecular Weight: 476.4962
Elemental Analysis: C, 63.02; H, 5.71; F, 11.96; N, 5.88; O, 13.43
Related CAS #: 2095128-30-4 2095128-17-7 (free acid)
Synonym: MA-0204; MA 0204; MA0204.
IUPAC/Chemical Name: (R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid
InChi Key: GYNMVDMBFKGCCR-QGZVFWFLSA-N
InChi Code: InChI=1S/C25H27F3N2O4/c1-17(14-23(31)32)6-5-13-33-22-8-4-3-7-20(22)16-30-18(2)15-29-24(30)19-9-11-21(12-10-19)34-25(26,27)28/h3-4,7-12,15,17H,5-6,13-14,16H2,1-2H3,(H,31,32)/t17-/m1/s1
SMILES Code: O=C(O)C[C@H](C)CCCOC1=CC=CC=C1CN2C(C)=CN=C2C3=CC=C(OC(F)(F)F)C=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 476.4962 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)
Bharat Lagu, Arthur F. Kluge, Effie Tozzo, Ross Fredenburg, Eric L. Bell, Matthew M. Goddeeris, Peter Dwyer, Andrew Basinski, Ramesh S. Senaiar, Mahaboobi Jaleel, Nirbhay Kumar Tiwari, Sunil K. Panigrahi, Narasimha Rao Krishnamurthy, Taisuke Takahashi, and Michael A. Patane
Publication Date (Web): July 31, 2018 (Letter)
MA-0204 was tested in vivo in mice and in vitro in patientderived muscle myoblasts (from Duchenne Muscular Dystrophy (DMD) patients); MA-0204 altered the expression of PPARδ target genes and improved fatty acid oxidation, which supports the therapeutic hypothesis for the study of MA-0204 in DMD patients.